Cyprotex today launches Cloe(R) Gateway, a new secure web portal for access to drug discovery services. The initial offering via Cloe(R) Gateway is a new enhanced version of our proprietary predictive software, Cloe(R) PK, which predicts whole body pharmacokinetics from simple in vitro ADME and physicochemical properties.

Commenting on the launch, Dr Anthony D. Baxter, Cyprotex's Chief Executive Officer, said: "I am delighted to announce the launch of our new and novel web portal Cloe(R) Gateway and its first product, an improved version of Cloe(R) PK. Cloe(R) PK, as a server based product, has been used by many of our customers for prediction of pharmacokinetic properties from early ADME data and found it to be very useful in decision making for candidate selection. Cyprotex have invested considerable time and effort improving the Cloe(R) PK model and we are proud to launch version 2.1 as an online service available via Cloe(R) Gateway. This will enable many more of our customers to utilise this excellent product on a simple pay-per-use model. The cost effectiveness of this approach will allow access of such predictive technologies to new audiences of scientists such as bench medicinal chemists. This approach to selling software solutions is new to the ADME / pharmacokinetic world and we anticipate it will grow to replace competitor products still being sold on the outdated server / license model.

The pharmaceutical industry has amassed a huge quantity of ADME data over the past few years and the availability of an online version of Cloe(R) PK though Cloe(R) Gateway will enable those companies to realise tremendous real added value from that data in the form of pharmacokinetic performance characteristics to enable faster, cheaper and better designed drugs to be developed.

I look forward to announcing further new products to be sold through Cloe(R) Gateway such as a human intestinal absorption model and a product to enable customers to access our largest selling product Cloe(R) Screen in the near future."